This highest-ranking interaction of our analysis was also confirmed in the pancreatic cancer cohort (P = 0.0058) where the 17 tumours with amplifications showed significantly more mutations at CTCF binding sites (FDR = 1.7 × 10− 4, FC = 1.18) compared to the 211 tumours lacking the amplifications (FDR = 0.042, FC = 1.04). The gene discussed is CTCF; the disease is neoplasm.